BREAKING NEWS: New drug approved by the FDA for Duchenne muscular dystrophy. Learn more about this new treatment option.

Medical Educational Resource

We're accelerating the delivery of treatments and cures.

What's New in Duchenne Muscular Dystrophy (DMD)

Activity Snapshot

Activity Type: 
Print/PDF
Release Date: 
Wednesday, June 1, 2022

Faculty

Emma Ciafaloni, MD, FAAN
Professor of Neurology, Pediatrics and Obstetrics and Gynecology, Director Pediatric Neuromuscular Medicine
University of Rochester
Activity Overview: 

This speaker slide set will provide an overview of Duchenne muscular dystrophy (DMD) and the current treatment landscape. Some topics included: clinical presentation and pathology, diagnostic considerations and current and emerging therapies.

Learning Objectives: 
  • Recognize signs/ symptoms of DMD
  • Identify ways to reduce diagnostic delay (eg, creatinine kinase, genetic testing, newborn screening)
  • Implement current treatment guidelines to manage DMD and related comorbidities
  • Use of multidisciplinary care to optimize outcomes (cardiac, pulmonary)
  • Mental health challenges, ways to reduce emotional toll of DMD
  • Identify emerging treatment strategies and ongoing clinical research (eg, gene-targeted therapy, exon-skipping) Advise patients of clinical trial opportunities